TheraCryf | R&D Day confirms potential
TheraCryf held a Research and Development Day (R&DD) concentrating on the progress of SFX-01, its lead clinical asset in the study relating to glioblastoma at Erasmus University in the Netherlands, and on the two new candidates acquired in the Chronos acquisition. The Erasmus study is demonstrating very encouraging initial results with the drug on track for trial in humans by early 2026. The R&DD explained the differentiated potential in the Orexin and dopamine transporter (DAT) inhibitor programmes, each of which could be in clinic within 18 months, subject to funding. Sourcing non-dilutive funding is TheraCryf's current priority. We published an initiation on TheraCryf which sets out the full investment thesis on 20th May. Despite its advantages, TheraCryf trades on a fraction of the rating of most peers with similar characteristics, has multiple prospective newsflow events due in 2024/25, and has a financial runway through towards the end of FY26.Evgen Pharma is a clinical stage drug development company. Co.'s pipeline is based on its proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane.
Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.
Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.